Format

Send to

Choose Destination
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Author information

1
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy. Electronic address: mariavittoriadieci@gmail.com.
2
Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France.
3
Montefiore Medical Center, Bronx, NY, USA; The Albert Einstein College of Medicine, Bronx, NY, USA.
4
Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department of Pathology, GZA Ziekenhuizen, Antwerp, Belgium.
5
Service de Biostatistique et d'Epidémiologie, Gustave Roussy, B2 M, RdC,114 rue Edouard-Vaillant, 94805, Villejuif, France; CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, 94805, France.
6
Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France; Inserm/University of Auvergne U1240, Clermont-Ferrand, France; School of Medicine, University of Auvergne, Clermont-Ferrand, France.
7
Division of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; University of Milan, School of Medicine, Milan, Italy.
8
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
9
Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA.
10
Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru.
11
Department of Pathology and Laboratory, Medicine, Indiana University, Indianapolis, USA.
12
Department of Pathology, Yale University School of Medicine, New Haven, USA.
13
Pathology Department, IIS, Fundacion Jimenez Diaz, UAM, Madrid, Spain.
14
Department of Pathology, Coney Island Hospital, NY, USA.
15
Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
16
Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.
17
National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, PA, USA.
18
Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
19
dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany.
20
German Breast Group, Neu-Isenburg, Germany.
21
Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
22
Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
23
New York University Medical School, Perlmutter Cancer Center, NY, USA.
24
Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
25
Translational Breast Cancer Genomic and Therapeutics Laboratory, Peter Mac Callum Cancer Center, Victoria, Australia; Breast Cancer Translational Research Laboratory, Jules Bordet Institute, Brussels, Belgium; Department of Pathology, GZA, Antwerp, Belgium.

Abstract

Morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer is gaining momentum as evidence strengthens the clinical relevance of this immunological biomarker. TILs in the post-neoadjuvant residual disease setting are acquiring increasing importance as a stratifying marker in clinical trials, considering the raising interest on immunotherapeutic strategies after neoadjuvant chemotherapy. TILs in ductal carcinoma in situ, with or without invasive carcinoma, represent an emerging area of clinical breast cancer research. The aim of this report is to update pathologists, clinicians and researchers on TIL assessment in both the post-neoadjuvant residual disease and the ductal carcinoma in situ settings. The International Immuno-Oncology Working Group proposes a method for assessing TILs in these settings, based on the previously published International Guidelines on TIL Assessment in Breast Cancer. In this regard, these recommendations represent a consensus guidance for pathologists, aimed to achieve the highest possible consistency among future studies.

KEYWORDS:

Breast cancer; Ductal carcinoma in situ; Neoadjuvant; Residual cancer burden; Residual disease; Tumor-infiltrating lymphocytes

PMID:
29024776
DOI:
10.1016/j.semcancer.2017.10.003
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center